FrancophonIA/ELRC3.0 huggingface dataset:
English: The active substance in Talmanco, tadalafil, belongs to a group of medicines called ‘phosphodiesterase type 5 (PDE5) inhibitors', which means that it blocks the PDE5 enzyme.
Slovenian: Zdravilna učinkovina v zdravilu Talmanco, tadalafil, spada v skupino zdravil, imenovanih zaviralci fosfodiesteraze tipa 5 (PDE5), kar pomeni, da zavira encim PDE5.
English: What is Talmanco and what is it used for?
Slovenian: Kaj je zdravilo Talmanco in za kaj se uporablja?
English: Talmanco is a medicine used to treat adults with pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity).
Slovenian: Zdravilo Talmanco se uporablja za zdravljenje odraslih bolnikov s pljučno arterijsko hipertenzijo (PAH) za izboljšanje telesne zmogljivosti (sposobnosti izvajanja telesne dejavnosti).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Talmanco have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Talmanco upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: It is not intended to provide practical advice on how to use Talmanco.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Talmanco tadalafil
Slovenian: tadalafil
English: For more information about treatment with Talmanco, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Talmanco preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: For practical information about using Talmanco, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Talmanco naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Talmanco is used in patients with class-II (slight limitation of physical activity) or class-III (marked limitation of physical activity) PAH.
Slovenian: Zdravilo Talmanco se uporablja pri bolnikih s pljučno arterijsko hipertenzijo razreda II (rahla omejitev fizične dejavnosti) ali razreda III (znatna omejitev fizične dejavnosti).
English: Talmanco is a ‘generic medicine'.
Slovenian: Je „generično zdravilo“.
English: Why is Talmanco approved?
Slovenian: Zakaj je bilo zdravilo Talmanco odobreno?
English: Talmanco can only be obtained with a prescription and treatment should be started and monitored by a doctor who has experience in the treatment of PAH.
Slovenian: Predpisovanje in izdaja zdravila Talmanco je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le zdravnik z izkušnjami z zdravljenjem pljučne arterijske hipertenzije.
English: Therefore, the CHMP's view was that, as for Adcirca, the benefit outweighs the identified risk.
Slovenian: Zato je menil, da njegove koristi enako kot pri zdravilu Adcirca odtehtajo znana tveganja.
English: The company also carried out studies that showed that it is ‘bioequivalent' to the reference medicine.
Slovenian: Opravila je tudi študije, ki so pokazale, da je zdravilo Talmanco biološko enakovredno referenčnemu zdravilu.
English: In patients with PAH, this lowers the blood pressure in the lungs and improves symptoms.
Slovenian: Tako se pri bolnikih s pljučno arterijsko hipertenzijo krvni tlak v pljučih zniža, simptomi pa se izboljšajo.
English: Talmanco contains the active substance tadalafil.
Slovenian: Zdravilo Talmanco vsebuje zdravilno učinkovino tadalafil.
English: The recommended dose is two tablets (40 mg) once a day.
Slovenian: Zdravilo Talmanco je na voljo v obliki tablet po 20 mg. Priporočeni odmerek je dve tableti (40 mg) enkrat na dan. Bolniki z blažjimi ali zmernimi težavami z ledvicami ali jetri morajo zdravljenje začeti z manjšim odmerkom.
English: How has Talmanco been studied?
Slovenian: Kako je bilo zdravilo Talmanco raziskano?
English: How does Talmanco work?
Slovenian: Kako zdravilo Talmanco deluje?
English: How is Talmanco used?
Slovenian: Kako se zdravilo Talmanco uporablja?
English: When the enzyme is blocked, a substance called ‘cyclic guanosine monophosphate' (cGMP) cannot be broken down and remains in the vessels where it causes widening of the blood vessels.
Slovenian: Njegovo zaviranje onemogoči razgradnjo snovi, imenovane ciklični gvanozinmonofosfat (cGMP).
English: This can result in serious vision loss and even blindness.
Slovenian: Posledica tega je lahko resno poslabšanje vida ali celo slepota.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Simbrinza on 18 July 2014.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Simbrinza, veljavno po vsej Evropski uniji, izdala 18. julija 2014.
English: What measures are being taken to ensure the safe and effective use of Simbrinza?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Simbrinza?
English: The full EPAR and risk management plan summary for Simbrinza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Simbrinza sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Simbrinza.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Simbrinza.
English: It will also benefit those patients who need a combination treatment and for whom previously authorised combinations containing the medicine timolol are not suitable.
Slovenian: Prav tako bo koristna za tiste bolnike, ki potrebujejo kombinirano zdravljenje in za katere že odobrene kombinacije, ki vsebujejo zdravilo timolol, niso primerne.
English: The CHMP therefore concluded that Simbrinza's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor CHMP je zato zaključil, da so koristi zdravila Simbrinza večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: Simbrinza must not be used in neonates or children under the age of two years and is not recommended in older children.
Slovenian: Zdravilo Simbrinza se ne sme uporabljati pri novorojenčkih in otrocih, mlajših od dvehlet, prav tako pa ga ni priporočljivo uporabljati pri starejših otrocih.
English: Simbrinza brinzolamide / brimonidine tartrate
Slovenian: Simbrinza brinzolamid/brimonidinijev tartrat
English: If other eye drops are also being used to lower eye pressure, they should be given at least 5 minutes apart.
Slovenian: Če se za zniževanje očesnega tlaka uporabljajo tudi druge kapljice za oči, mora med dajanjem posameznih zdravil preteči najmanj 5 minut.
English: What benefits of Simbrinza have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Simbrinza izkazalo v študijah?
English: What is Simbrinza and what is it used for?
Slovenian: Kaj je zdravilo Simbrinza in za kaj se uporablja?
English: Other information about Simbrinza
Slovenian: Druge informacije o zdravilu Simbrinza
English: A risk management plan has been developed to ensure that Simbrinza is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Simbrinza je bil pripravljen načrt obvladovanja tveganj.
English: Simbrinza is given as one drop into the affected eye(s) twice a day.
Slovenian: Zdravilo Simbrinza se daje z eno kapljico v prizadeto oko (oči) dvakrat na dan.
English: It is not intended to provide practical advice on how to use Simbrinza.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Simbrinza was shown to be as effective as the combination treatment.
Slovenian: Zdravilo Simbrinza je bilo prav tako učinkovito kot kombinirano zdravljenje.
English: Both medicines have been used separately to reduce eye pressure for several years in the EU and their combination reduces the pressure inside the eye more effectively than either medicine alone.
Slovenian: Obe zdravili se v EU že več let ločeno uporabljata za zniževanje očesnega tlaka, v kombinaciji pa učinkoviteje znižata tlak v očesu kot katera koli od obeh učinkovin posamično.
English: Why is Simbrinza approved?
Slovenian: Zakaj je bilo zdravilo Simbrinza odobreno?
English: The most common side effects in studies with Simbrinza were ocular hyperaemia (red eye) and allergic reactions in the eye, which occurred in about 6 to 7% of patients, and dysgeusia (taste disturbances) in about 3% of patients.
Slovenian: Najpogostejši neželeni učinki v študijah z zdravilom Simbrinza so bili očesna hiperemija (rdeče oko) in očesne alergijske reakcije, ki so se pojavile pri približno 6 do 7 % bolnikov, ter disgevzija (motnje okušanja), ki se je pojavila pri približno 3 % bolnikov.
English: Simbrinza is used when treatment with other medicines containing only one active substance have been tried but has not reduced the intra-ocular pressure sufficiently.
Slovenian: Zdravilo Simbrinza se uporabi, potem ko se preskusi zdravljenje z drugimi zdravili, ki vsebujejo samo eno zdravilno učinkovino, vendar se intraokularni tlak ne zniža v zadostni meri.
English: It must also not be used in patients receiving certain types of antidepressants, patients with severely reduced kidney function, or in patients with hyperchloraemic acidosis (excess acid in the blood caused by too much chloride).
Slovenian: Prav tako se ne sme uporabljati pri bolnikih, ki prejemajo določene vrste antidepresivov, bolnikih z močno zmanjšanim delovanjem ledvic in pri bolnikih s hiperkloremično acidozo (preveliko kislostjo krvi zaradi čezmerne količine klorida).
English: A second main study involving 890 patients compared Simbrinza with a combination treatment of brinzolamide and brimonidine tartrate given as separate drops.
Slovenian: V drugi glavni študiji, v kateri je sodelovalo 890 bolnikov, so zdravilo Simbrinza primerjali s kombiniranim zdravljenjem z brinzolamidom in brimonidinijevim tartratom, ki sta se dajala z ločenimi kapljicami.
English: As regards safety, the side effects reported with Simbrinza were what would be expected with the individual active substances and raised no major concerns.
Slovenian: Kar zadeva varnost, so bili neželeni učinki, o katerih so poročali pri uporabi zdravila Simbrinza, takšni, kot bi jih pričakovali pri uporabi posameznih zdravilnih učinkovin, in niso povzročili večjih skrbi.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Simbrinza was shown to be more effective than either active substance used alone and at least as effective as the combination of the active substances given as separate eye drops.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo dokazano, da je zdravilo Simbrinza učinkovitejše od katere koli od obeh zdravilnih učinkovin, uporabljenih posamično, in vsaj tako učinkovito kot kombinacija obeh zdravilnih učinkovin, danih z ločenimi kapljicami za oko.
English: Brinzolamide works by blocking an enzyme called carbonic anhydrase, which produces bicarbonate needed for the production of the aqueous humour, while brimonidine tartrate blocks another enzyme known as adenylate cyclase, which is also involved in the production of the aqueous humour.
Slovenian: Brinzolamid deluje tako, da zavira encim, imenovan karboanhidraza, ki tvori bikarbonat, ki je potreben za tvorbo prekatne vodice, brimonidinijev tartrat pa zavira drug encim, imenovan adenilat-ciklaza, ki prav tako sodeluje pri tvorbi prekatne vodice.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Simbrinza, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Simbrinza in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: The reduction in intra-ocular pressure after 3 months was greater in patients using Simbrinza (an average fall of 7.9 mmHg) than in those using either brinzolamide or brimonidine tartrate (6.5 and 6.4 mmHg, respectively).
Slovenian: Znižanje intraokularnega tlaka po 3 mesecih je bilo večje pri bolnikih, ki so uporabljali zdravilo Simbrinza (povprečno znižanje za 7,9 mmHg), kot pri tistih, ki so uporabljali bodisi brinzolamid bodisi brimonidinijev tartrat (6,5 oziroma 6,4 mmHg).
English: For more information about treatment with Simbrinza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Simbrinza preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Open-angle glaucoma (a condition where the aqueous humour, the watery fluid inside the eyeball, cannot drain away properly) and other causes of high pressure in the eye increase the risk of damage to the retina and the optic nerve (the nerve that sends signals from the eye to the brain).
Slovenian: Glavkom odprtega zakotja (bolezen, pri kateri se prekatna vodica, ki je vodi podobna tekočina v zrklu, ne more pravilno izločati iz očesa) in drugi vzroki visokega tlaka v očesu povečajo tveganje za poškodbe mrežnice in optičnega živca (živca, ki pošilja signale iz očesa v možgane).
English: One main study involved 560 patients with ocular hypertension or open-angle glaucoma, whose average intra-ocular pressure before treatment, measured in units called mmHg, was 26 mmHg.
Slovenian: V eni glavni študiji je sodelovalo 560 bolnikov z očesno hipertenzijo ali glavkomom odprtega zakotja, pri katerih je povprečni intraokularni tlak pred zdravljenjem, merjen v enotah, imenovanih mmHg, znašal 26 mmHg.
English: For practical information about using Simbrinza, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Simbrinza naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: What are the risks associated with Simbrinza?
Slovenian: Kakšna tveganja so povezana z zdravilom Simbrinza?
English: Brimonidine also increases the drainage of aqueous humour from the front of the eye.
Slovenian: Brimonidin prav tako poveča izločanje prekatne vodice iz sprednjega dela očesa.
English: Simbrinza must not be used in patients who are hypersensitive (allergic) to the active substances, any of the other ingredients, or to sulphonamides (a class of antibiotics).
Slovenian: Zdravilo Simbrinza se ne sme uporabljati pri bolnikih, ki so preobčutljivi za (alergični na) zdravilni učinkovini, katero koli drugo sestavino zdravila ali sulfonamide (vrsto antibiotikov).
English: Simbrinza can only be obtained by prescription.
Slovenian: Izdaja zdravila Simbrinza je le na recept.
English: For the full list of all side effects reported with Simbrinza, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Simbrinza, glejte navodilo za uporabo.
English: The average reduction in intra-ocular pressure with Simbrinza after 3 months was 8.5 mmHg compared with 8.3 mmHg with the combination.
Slovenian: Intraokularni tlak se je po 3 mesecih uporabe zdravila Simbrinza v povprečju znižal za 8,5 mmHg, pri uporabi kombinacije pa za 8,3 mmHg.
English: The active substances in Simbrinza, brinzolamide and brimonidine tartrate, help to reduce intra-ocular pressure by reducing the production of aqueous humour.
Slovenian: Zdravilni učinkovini v zdravilu Simbrinza, brinzolamid in brimonidinijev tartrat, zmanjšata nastajanje prekatne vodice in tako pomagata znižati intraokularni tlak.
English: Simbrinza is an eye drop solution that contains two active substances: brinzolamide and brimonidine tartrate.
Slovenian: Zdravilo Simbrinza je raztopina v obliki kapljic za oko, ki vsebuje dve zdravilni učinkovini: brinzolamid in brimonidinijev tartrat.
English: Simbrinza is used to reduce intra-ocular pressure (pressure inside the eye) in adults with ocular hypertension (high intra-ocular pressure) or in those with an eye condition known as open-angle glaucoma.
Slovenian: Zdravilo Simbrinza se uporablja za zniževanje intraokularnega tlaka (tlaka v očesu) pri odraslih z očesno hipertenzijo (visokim intraokularnim tlakom) ali tistih, ki imajo očesno bolezen, imenovano glavkom odprtega zakotja.
English: Simbrinza has been shown to be more effective in reducing eye pressure than either brinzolamide or brimonidine tartrate used alone.
Slovenian: Zdravilo Simbrinza je bilo učinkovitejše pri znižanju očesnega tlaka od samega brinzolamida ali brimonidinijevega tartrata.
English: Having the two active substances in one eye drop will improve convenience and adherence to treatment for patients who are not adequately controlled with either brimonidine or brinzolamide alone.
Slovenian: Kombinacija obeh zdravilnih učinkovin v eni sami kapljici za oči bo priročnejša za bolnike, pri katerih bolezen ni zadovoljivo nadzorovana s samim brimonidinom ali brinzolamidom, in bo prispevala k temu, da se bodo držali predpisanega zdravljenja.
English: How does Simbrinza work?
Slovenian: Kako zdravilo Simbrinza deluje?
English: How is Simbrinza used?
Slovenian: Kako se zdravilo Simbrinza uporablja?
English: This summary was last updated in 04-2009.
Slovenian: Povzetek je bil nazadnje posodobljen 02-2009.
English: It is available as capsules (white: 1.5 mg; pink: 3 mg; orange: 4.5 mg; orange and pink: 6 mg).
Slovenian: Na voljo je v obliki kapsul (rumenih: 1,5 mg, rožnatih: 3 mg; oranžnih: 4,5 mg; oranžnih in rožnatih: 6 mg).
English: This means that Rivastigmine Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exelon.
Slovenian: To pomeni, da je zdravilo Rivastigmine Teva podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Exelon.
English: Other information about Rivastigmine Teva:
Slovenian: Druge informacije o zdravilu Rivastigmine Teva:
English: Rivastigmine Teva should be given twice a day, with morning and evening meals.
Slovenian: Zdravilo Rivastigmine Teva se daje dvakrat na dan ob zajtrkih in večerjah.
English: What are the benefit and risk of Rivastigmine Teva?
Slovenian: Kakšne so koristi in tveganja, povezana z zdravilom Rivastigmine Teva?
English: In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a chemical that allows nerve cells to communicate with each other).
Slovenian: Pri bolnikih z alzheimerjevo demenco ali demenco zaradi parkinsonove bolezni v možganih odmrejo določene živčne celice, zaradi česar se znižajo ravni nevrotransmiterja acetilholina (kemične snovi, ki omogoča medsebojno komunikacijo med živčnimi celicami).
English: Rivastigmine Teva is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Slovenian: Zdravilo Rivastigmine Teva se uporablja za zdravljenje bolnikov z blago do zmerno hudo alzheimerjevo demenco, napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) RIVASTIGMINE TEVA EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) RIVASTIGMINE TEVA Povzetek EPAR za javnost
English: Treatment with Rivastigmine Teva should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease.
Slovenian: Zdravljenje z zdravilom Rivastigmine Teva mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem alzheimerjeve bolezni ali demence pri bolnikih s parkinsonovo boleznijo.
English: Rivastigmine Teva is a ‘generic medicine'.
Slovenian: Rivastigmine Teva je „generično zdravilo“.
English: Because Rivastigmine Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Slovenian: Glede na to, da je Rivastigmine Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, se upošteva, da so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The Committee recommended that Rivastigmine Teva be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Rivastigmine Teva odobri dovoljenje za promet.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Rivastigmine Teva has been shown to have comparable quality and to be bioequivalent to Exelon.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v s skladu z zahtevami EU dokazano, da ima zdravilo Rivastigmine Teva primerljivo raven kakovosti kot zdravilo Exelon ter da mu je biološko enakovredno.
English: Treatment should only be started if a caregiver is available who will regularly monitor the use of Rivastigmine Teva by the patient.
Slovenian: Zdravljenje se začne samo ob prisotnosti negovalca, ki redno nadzoruje uporabo zdravila Rivastigmine Teva pri bolniku.
English: The full EPAR for the reference medicine can also be found on the EMEA's website.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za referenčno zdravilo je na voljo na spletni strani EMEA.
English: In patients who tolerate this dose, it can be increased in 1.5-mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day.
Slovenian: Pri bolnikih, ki prenašajo ta odmerek, se lahko ta postopoma povečuje za 1,5 mg, vendar ne pogosteje kot vsaka dva tedna, dokler se ne doseže stalni odmerek 3 do 6 mg dvakrat na dan. Za dosego največje učinkovitosti se uporabi največji odmerek, ki ga bolnik še prenaša, vendar odmerek ne sme preseči 6 mg dvakrat na dan.
English: Because Rivastigmine Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (the two medicines produce the same levels of the active substance in the body).
Slovenian: Ker je zdravilo Rivastigmine Teva generično zdravilo, so bile študije omejene na preskuse, s katerimi se dokazuje, da je biološko enakovredno referenčnemu zdravilu (tj. da zdravili dosegata enake ravni zdravilne učinkovine v telesu).
English: Rivastigmine Teva can also be used to treat mild to moderately severe dementia in patients with Parkinson's disease.
Slovenian: Zdravilo Rivastigmine Teva se lahko uporablja tudi za zdravljenje blage do zmerno hude demence pri bolnikih s parkinsonovo boleznijo.
English: The European Commission granted a marketing authorisation valid throughout the EU for Rivastigmine Teva to Teva Pharma B.V. on 17 April 2009.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Rivastigmine Teva, veljavno po vsej Evropski uniji, odobrila družbi Teva Pharma B.V.
English: Rivastigmine Teva is a medicine containing the active substance rivastigmine.
Slovenian: Rivastigmine Teva je zdravilo, ki vsebuje zdravilno učinkovino rivastigmin.
English: Rivastigmine Teva allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease.
Slovenian: Teva z blokiranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi alzheimerjeve demence in demence zaradi parkinsonove bolezni ublažijo.
English: Why has Rivastigmine Teva been approved?
Slovenian: Zakaj je bilo zdravilo Rivastigmine Teva odobreno?